Jørgen Kjems
Has participated in:
-
Dual‐Targeting of the HER2 Cancer Receptor with an Antibody‐Directed Enzyme and a Nanobody‐Guided MMAE Prodrug Scaffold
-
Functionalized Acyclic (l)‐Threoninol Nucleic Acid Four‐Way Junction with High Stability In Vitro and In Vivo
-
Functionalized Acyclic (l)‐Threoninol Nucleic Acid Four‐Way Junction with High Stability In Vitro and In Vivo
-
The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer